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Abacavir (ABC) (Ziagen, GlaxoWellcome) is a novel nucleo-
side analog that inhibits in a competitive fashion the HIV
reverse transcriptase by blocking dGTP incorporation into the
nascent DNA. Preliminary studies have shown that ABC has
comparable, or even greater, potency that the currently
approved nucleoside analogs, with a mean IC50 of 0.26 mmol/
L. The antiretroviral e¡ect of ABC is synergistic with the
activity of zidovudine, zalcitabine, lamivudine, stavudine and
didanosine [1]. In clinical trials ABC combined with two
other nucleosides has demonstrated to be a potent regimen for
naive patients [2], and a good alternative for intensi¢cation [3]
and simpli¢cation [4] in pretreated subjects. However, due to
cross-resistance mainly with zidovudine and lamiduvine, the
role of ABC in rescue regimens seems to be limited [5].
In the ¢rst clinical trials ABC seemed to have good toler-
ability, with adverse events that included nausea, diarrhoea,
headache, rash, malaise, asthenia and fatigue [6]. However, it
was not clear whether side-e¡ects were attributable toABC or
to other drugs [6]. Of note, 3% of these patients developed a
serious idiosyncratic hypersensitivity reaction (HSR), charac-
terized by fever, rash, gastrointestinal intolerance and/or
malaise. In most instances patients complained of more than
two symptoms [7], and HSR resolved when ABC was inter-
rupted. However, the reintroduction of the drug produced an
extremely severe and even lethal reaction [8]. Although ABC
toxicity seemed to be rare, further studies have reported rates
of drug discontinuation raising up to10^22% [7^9].
To assess the safety of ABC in the clinical practice, we have
analysed its tolerability in 172 consecutive patients who started
a regimen including ABC in our outpatient clinic. ABC (300
mg twice a day) was prescribed in most instances as part of a
rescue intervention in patients failing previous therapy
(67.5%). Alternatively, it was introduced to replace a drug
causing toxicity (20.2%) or following a simpli¢cation proto-
col in which protease inhibitors were replaced byABC main-
taining the same two nucleosides (9.1%).Treatment with ABC
had to be discontinued in 14 (8.1%). In seven (4%) patients
symptoms related to HSRwere reported: one had fever and
rash, four had only rash, and two had fever, malaise and asthe-
nia. Half of the interruptions were due to other manifesta-
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tions: three patients complained of severe asthenia, two suf-
fered gastrointestinal intolerance and two anxiety. All these
adverse events, except anxiety, were similar to those reported
in previous studies. Symptoms disappeared when ABC was
stopped. Some authors have claimed that ABC does not need
to be removed if rash is the only manifestation [10]. However,
minor symptoms associated with rash are quite common and
doctors should be concerned about the potential of a more
severe reaction, and allow ABC to be withdrawn more fre-
quently.
In conclusion, in a clinical setting ABC was relatively safe.
Overall, 4% of subjects developed hypersensitivity, which
always resolved when the drug was discontinued. However,
the total rate of discontinuation was 8%, which is slightly
higher than that reported in original clinical trials.
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Gram-positive anaerobic cocci (GPAC) account for one-
fourth to one-third of all anaerobic isolates recovered from
clinical specimens, and Gram-negative anaerobic cocci
(GNAC), predominantly the veillonellae, constitute up to
6.3% [1^3]. Anaerobic cocci have often been encountered in
head and neck, lung, intestinal, gynecologic and soft-tissue
infections [4,5]. These organisms have been considered as a`n
important but neglected group'; reasons include di¤culties
with laboratory isolation, their frequent involvement in poly-
microbial infections, and anticipated susceptibility to most
antimicrobial agents used to treat anaerobic infections [2].
However, recent studies have reported an increase in resistance
of anaerobic cocci to b-lactams, lincosamides and nitroimida-
zoles [6^8].
The aims of this study were: to evaluate the commonest
species of anaerobic cocci isolated in the university hospital of
pulmonary diseases and several other university hospitals in
So¢a, to determine the resistance patterns to four antimicro-
bial agents, considered as drugs of choice for treating anaero-
bic infections, and to assess the resistance to more than one
agent among the isolates.
FromOctober1996 toMay1999, 42 consecutive non-dupli-
cate clinical isolates of anaerobic cocci from 41 adult patients
were evaluated, comprising Peptostreptococcus anaerobius (seven
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